Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 2/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24665373 | 1.00 | LTA4H (0.38) | LTA4HMAPTSCN9AFFAR1THRB | |
| SCHEMBL30006457 | 0.92 | LTA4H (0.45) | LTA4HSCN9AHDAC6KCNH2 | |
| SCHEMBL29123526 | 0.90 | PTPN1 (0.42) | MAPTSCN9AFFAR1THRBGRN | |
| SCHEMBL27243633 | 0.89 | LTA4H (0.40) | LTA4HMAPTSCN9AFFAR1THRB | |
| SCHEMBL27243634 | 0.89 | LTA4H (0.40) | LTA4HMAPTSCN9AFFAR1THRB | |
| SCHEMBL29123536 | 0.89 | MAPK1 (0.42) | MAPTSCN9AFFAR1HDAC1HDAC6 | |
| SCHEMBL24664167 | 0.89 | MAPK1 (0.42) | MAPTSCN9AFFAR1HDAC1HDAC6 | |
| SCHEMBL24665367 | 0.89 | LTA4H (0.38) | LTA4HMAPTFFAR1THRBPKM | |
| SCHEMBL30006150 | 0.89 | LTA4H (0.38) | LTA4HMAPTFFAR1THRBPKM | |
| SCHEMBL24665374 | 0.86 | PTPN1 (0.39) | MAPTSCN9AFFAR1GRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628163-A1 | NOVEL HETEROARYL AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| EP-4323062-B1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2025-07-23 | — | — | EP | disclosed |
| US-20240199593-A1 | Novel Heteroaryl Aminopropanol Derivatives | NOVARTIS PHARMA AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| EP-4323062-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20220348566-A1 | Novel Heteroaryl Aminopropanol Derivatives | NOVARTIS AG (CH) | 2022-11-03 | — | — | US | disclosed |
| WO-2022219546-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348566-A1 | Novel Heteroaryl Aminopropanol Derivatives | CYP11B2, CYP11B1, CYP3A43 | LTA4H 953/4885MAPT 3003/4885SCN9A 1243/4885 |
| US-20240199593-A1 | Novel Heteroaryl Aminopropanol Derivatives | CYP3A43, CYP3A5, CYP51A1 | LTA4H 1384/4885MAPT 462/4885SCN9A 2922/4885 |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | CYP3A43, CYP11B2, ADRB3 | LTA4H 1006/4885MAPT 2923/4885SCN9A 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.